It is known that the adherence capacity of T lymphocytes of cancer patients is reduced. Restoration of the cellularadherence capacity might be useful for the treatment of cancer. The study was conducted in two parts. In the first part, a total of 265 blood samples were taken from larynx/pharynx squamous cell carcinoma patients in the years 2000 - 2008 and subsequently analyzed. The blood samples were divided into the following groups: 1) exposure to a magnetic field of 0.05 mT (n=30), 2) 0.1 mT (n=30), 3) 0.5 mT (n=76), 4) 1 mT (n=60) and 5) 10 mT (n=69), 6) no exposure (n=?). Additionally, blood samples of 316 voluntary blooddonors were examined as a control group. In the second part, further blood samples from a fraction of the carcinoma patients from part 1 were analyzed simultaneously, to rule out a possible time factor in the first part, as the samples were analyzed over several years. The following groups were tested in these subgroups: 7) exposure to a magnetic field of 0.01 mT (n=20) , 8) 0.05 mT (n=20) and 9) 0.1 mT (n=20), 10) no exposure (n=?). Blood samples of 30 patients with chronic sensorineural hearing loss were used as a control group.
33 cm high cylindrical coil with a diameter of 30 cm; test tubes placed at the center of the coil; the temperature during the experiment was 37°C; the non-homogeneity of the field within the test tube was in the vicinity of 1 %
Lee YJ et al.
(2016):
Effects of exposure to extremely low-frequency electromagnetic fields on the differentiation of Th17 T cells and regulatory T cells
Cocek A et al.
(2008):
Changes of leukocyte adherence ability under the influence of magnetic field in the course of a treatment of patients with laryngeal and pharyngeal carcinoma
Jandova A et al.
(2005):
Effects of Magnetic Field 0.1 and 0.05 mT on Leukocyte Adherence Inhibition
Jandova A et al.
(2004):
Effects of Sinusoidal 0.5 mT Magnetic Field on Leukocyte Adherence Inhibition
Santini MT et al.
(2003):
Effects of a 50 Hz sinusoidal magnetic field on cell adhesion molecule expression in two human osteosarcoma cell lines (MG-63 and Saos-2)